Earnings ·
Bionano reports Q3 revenue of $8.3M, up 12%, and reiterates full-year guidance
BNGOBionano Genomics, Inc.
Bionano Genomics reported third-quarter 2026 total revenue of $8.3 million, a 12% increase from $7.4 million in the prior year period. Consumables revenue rose 24% to $4.7 million, and flowcell sales increased 18% to 9,870 units. Gross margin improved to 48% from 46%, while operating expenses decreased 12% to $10.5 million. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted growing reimbursement pathways for optical genome mapping tests. Bionano Genomics provides genome analysis solutions, including optical genome mapping platforms and diagnostic services.